Welcome to the Empowered Patient Podcast with Karen Jagoda. This show is a window into the latest innovations in applying generative AI, novel therapeutics and vaccines, and the changing dynamics in the medical and healthcare environment. One focus is on how providers, pharmaceutical companies, and payers are empowering patients. In addition, conversations are often about how providers, care facilities, pharmaceutical companies, and payers are being empowered by technology to improve patient outcomes and reduce friction across the healthcare landscape.
Popular Topics
- Virtual and digital health
- Use of AI, ML, and LLM in healthcare and drug discovery, development, trials
- Value-based healthcare
- Precision and stratified medicine
- Integration of digital technology into existing workflow and procedures
- Next-generation immuno, cell, and gene therapies
- Vaccines
- Biomarkers, sequencing, and imaging
- Rare diseases
- MedTech and medical devices
- Clinical trials
- Addressing Social Determinants of Health
- Treating chronic conditions like obesity and pain
- Clinician and staff burnout
The audience includes life science leaders, researchers, medical professionals, patient advocates, digital health entrepreneurs, patients, caregivers, healthcare solution providers, students, journalists, and investors.
Check out our new EmpoweredPatient.Solutions site where you can quickly search all of the Empowered Patient Podcast interviews by any word or phrase to identify useful resources, potential partners, and insights about the life sciences landscape.
Novel Long-Acting Antipsychotic Prodrug for Schizophrenia with Dr. Sam Clark Terran Biosciences TRANSCRIPT
Download PDFMar 20, 2025
Dr. Sam Clark, Founder and CEO of Terran Biosciences, is developing a long-acting once-daily formulation of a new class of antipsychotic drugs to treat schizophrenia. The use of a prodrug approach to modify the new drug Cobenfy allows for improved bioavailability and has been shown to have fewer side effects...
Mar 20, 2025
Dr. Sam Clark, Founder and CEO of Terran Biosciences, is developing a long-acting once-daily formulation of a new class of antipsychotic drugs to treat schizophrenia. The use of a prodrug approach to modify the new drug Cobenfy allows for improved bioavailability and has been shown to have fewer side effects...
Non-Hallucinogenic Psychedelics to Induce Neuroplasticity in the Treatment of Mental Health Disorders with Joe Tucker Enveric Biosciences TRANSCRIPT
Download PDFMar 19, 2025
Joe Tucker, CEO of Enveric Biosciences, is developing non-hallucinogenic psychedelic drugs that aim to induce neuroplasticity and beneficial changes in the brains of patients with mental health disorders. The FDA rejected the approval of MDMA for PTSD treatment due to concerns about the inability to run blind trials to...
Mar 19, 2025
Joe Tucker, CEO of Enveric Biosciences, is developing non-hallucinogenic psychedelic drugs that aim to induce neuroplasticity and beneficial changes in the brains of patients with mental health disorders. The FDA rejected the approval of MDMA for PTSD treatment due to concerns about the inability to run blind trials to...
Oral Drug Therapy for Slowing Progression of Alzheimer’s and Lewy Body Dementia with Lisa Ricciardi and Dr. Tony Caggiano Cognition Therapeutics TRANSCRIPT
Download PDFMar 12, 2025
Lisa Ricciardi, CEO, and Dr. Tony Caggiano, Chief Medical Officer at Cognition Therapeutics, are developing effective treatments for neurological disorders, particularly Alzheimer's disease and dementia with Lewy bodies (DLB). While DLB is related to Parkinson's, sharing symptoms include hallucinations, sleep...